LYCOS RETRIEVER 
Vioxx: Markets
built 450 days ago
Vioxx (rofecoxib) is a Cox-2 inhibitor, a class of drug that was released on the U.S. market several years ago. This class of drug was to be the next step in treating osteoarthritis and other types of pain.
Source:
The prescription medication Vioxx has been in the national spotlight recently, as evidence of deadly complications have emerged. Vioxx is a COX-2 Inhibitor designed by Merck Pharmaceuticals that was ordered off American and European markets on April 7th, 2005 after evidence of severe and potentially deadly side effects emerged.
Source:
Taken by 84 million people since 1999 and used by 2 million people worldwide at the time of its withdrawal from the market, Vioxx made Merck nearly $3 billion in 2004. It accounted for an impressive 12% of the company's revenue.
Source:
Vioxx was voluntarily withdrawn from the market in September of 2004 by Merck & Co., Inc., due to its dangerous and possibly deadly side effects. Vioxx is used by more than two million people worldwide to treat arthritis, menstrual pain, and other medical conditions.
Source:
Celebrex and Vioxx were introduced to the U.S. market in 1999 as arthritis painkillers. Both drugs, alongside Bextra, are part of a class of drugs called COX-2 inhibitors that were immediately popular when emerging onto the market.
Source:
If you are currently taking the prescription drug Vioxx you should seek medical attention and discontinue use of the medication immediately. On September 30, 2004 Merck & Co., Inc. has voluntarily taken the arthritis drug off of the market due to dangerous cardiovascular side effects that pose a variety of serious threats to patients. The Food and Drug Administration approved of Vioxx in 1999, and released it to the public in May of that year despite clinical tests that showed links to hypertension. The drug, which is taken orally, is used to treat arthritis, menstrual pain, and other types of pain in adults, and was recently approved for use in treating children before it was recalled in September.
Source:
MORE ABOUT
Markets